Net Loss of Suven Life Sciences reported to Rs 77.31 crore in the quarter ended September 2025 as against net loss of Rs 49.64 crore during the previous quarter ended September 2024. Sales declined 64.20% to Rs 0.92 crore in the quarter ended September 2025 as against Rs 2.57 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales0.922.57 -64 OPM %-8670.65-2031.52 - PBDT-75.99-48.19 -58 PBT-77.31-49.64 -56 NP-77.31-49.64 -56 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News

Net Loss of Suven Life Sciences reported to Rs 51.52 crore in the quarter ended June 2025 as against net loss of Rs 28.04 crore during the previous quarter ended June 2024. Sales rose 85.15% to Rs 1.87 crore in the quarter ended June 2025 as against Rs 1.01 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1.871.01 85 OPM %-2713.90-3023.76 - PBDT-50.15-26.55 -89 PBT-51.52-28.04 -84 NP-51.52-28.04 -84 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 August 2025.Powered by Capital Market - Live News

Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD).  The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery �sberg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase 2b trial being conducted in exclusively in USA under FDA IND. Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD.� said  Venkat Jasti, Chairman and MD of Suven Life Sciences.Powered by Capital Market - Live News